Overview

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The objective of the current study is to evaluate the effect of once daily itraconazole on the pharmacokinetics of BI 409306 in poor (PM) and extensive metabolisers (EM) of CYP2C19.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

BI 409306
Hydroxyitraconazole
Itraconazole